Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 7/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5329400 | 0.85 | HRH3 (0.48) | AKT2TAAR1CYP2A6LOXL2 | |
| SCHEMBL5612851 | 0.82 | NISCH (0.42) | AKT2L3MBTL1 | |
| SCHEMBL13078874 | 0.80 | METAP2 (0.32) | AKT2 | |
| SCHEMBL5612800 | 0.79 | RAB9A (0.49) | AKT2KDM4EL3MBTL1KMT2A | |
| SCHEMBL1823584 | 0.79 | METAP2 (0.44) | TAAR1KDM4EALDH1A1BLMKMT2A | |
| SCHEMBL19938006 | 0.78 | BRS3 (0.35) | AKT2SLC6A2 | |
| SCHEMBL21274654 | 0.78 | TAAR1 (0.49) | AKT2TAAR1CYP1A2KDM4EALDH1A1 | |
| SCHEMBL28164912 | 0.78 | CHEK1 (0.43) | — | |
| SCHEMBL28876711 | 0.78 | AKT2 (0.31) | AKT2 | |
| SCHEMBL28732240 | 0.76 | TP53 (0.47) | KDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414384-B2 | P300/CBP hat inhibitors | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| EP-3752250-B1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2022-08-03 | — | — | EP | disclosed |
| US-20210061762-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20210061762-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| EP-3752250-A1 | P300/CBP HAT INHIBITORS | Constellation Pharmaceuticals, Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| WO-2019161157-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMCEUTICALS, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| WO-2019161157-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMCEUTICALS, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414384-B2 | P300/CBP hat inhibitors | EP300, HDAC1, KAT2A | AKT2 1048/4885MAOB 2465/4885TAAR1 2583/4885 |
| US-20210061762-A1 | P300/CBP HAT INHIBITORS | EP300, HDAC1, KAT2A | AKT2 1048/4885MAOB 2465/4885TAAR1 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.